Blueprint Ebit vs Interest Expense Analysis

BPMC Stock  USD 88.78  1.58  1.81%   
Blueprint Medicines financial indicator trend analysis is way more than just evaluating Blueprint Medicines Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Blueprint Medicines Corp is a good investment. Please check the relationship between Blueprint Medicines Ebit and its Interest Expense accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

Ebit vs Interest Expense

JavaScript chart by amCharts 3.21.1520162018202020222024-650M-600M-550M-500M-450M-400M-350M-300M-250M-200M-150M-100M-50M050M100M150M200M250M300M 5M10M15M20M25M30M35M40M45M50M55M60M
JavaScript chart by amCharts 3.21.15Ebittotal: -3.1BInterest Expensetotal: 225.8M

Ebit vs Interest Expense Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Blueprint Medicines Corp Ebit account and Interest Expense. At this time, the significance of the direction appears to have strong contrarian relationship.
EbitInterest ExpenseDiversified Away100%
The correlation between Blueprint Medicines' Ebit and Interest Expense is -0.54. Overlapping area represents the amount of variation of Ebit that can explain the historical movement of Interest Expense in the same time period over historical financial statements of Blueprint Medicines Corp, assuming nothing else is changed. The correlation between historical values of Blueprint Medicines' Ebit and Interest Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit of Blueprint Medicines Corp are associated (or correlated) with its Interest Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Interest Expense has no effect on the direction of Ebit i.e., Blueprint Medicines' Ebit and Interest Expense go up and down completely randomly.

Correlation Coefficient

-0.54
Relationship DirectionNegative 
Relationship StrengthVery Weak

Ebit

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.
Most indicators from Blueprint Medicines' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Blueprint Medicines Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
At present, Blueprint Medicines' Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 2.1 B, whereas Sales General And Administrative To Revenue is forecasted to decline to 1.12.
 2022 2023 2024 2025 (projected)
Interest Expense16.8M51.6M59.3M62.3M
Depreciation And Amortization20.1M11.7M13.4M7.7M

Blueprint Medicines fundamental ratios Correlations

0.530.150.790.770.540.860.380.11-0.730.760.510.870.650.550.770.990.910.940.580.180.880.640.820.950.5
0.530.220.91-0.090.980.780.240.85-0.930.39-0.170.280.97-0.10.260.430.580.660.990.070.830.990.850.630.97
0.150.220.30.110.080.3-0.820.27-0.220.50.120.260.350.140.050.130.230.230.140.180.30.180.290.060.43
0.790.910.30.280.890.950.270.67-0.970.680.060.60.970.130.580.720.810.870.930.220.980.960.980.810.9
0.77-0.090.110.28-0.090.450.17-0.49-0.160.610.780.850.080.770.690.850.610.57-0.040.130.450.030.350.61-0.08
0.540.980.080.89-0.090.740.370.81-0.920.33-0.150.230.94-0.130.280.440.60.660.990.050.810.980.820.660.93
0.860.780.30.950.450.740.290.51-0.910.780.130.730.880.230.730.80.850.90.80.410.970.850.990.820.75
0.380.24-0.820.270.170.370.290.02-0.33-0.02-0.020.190.18-0.010.390.360.30.320.34-0.010.290.330.30.450.02
0.110.850.270.67-0.490.810.510.02-0.720.17-0.63-0.040.79-0.40.05-0.020.210.320.810.080.520.790.610.190.85
-0.73-0.93-0.22-0.97-0.16-0.92-0.91-0.33-0.72-0.640.06-0.48-0.970.03-0.53-0.63-0.79-0.85-0.94-0.21-0.93-0.96-0.95-0.79-0.88
0.760.390.50.680.610.330.78-0.020.17-0.640.310.760.590.170.660.730.820.820.40.30.760.470.750.660.44
0.51-0.170.120.060.78-0.150.13-0.02-0.630.060.310.47-0.080.650.190.610.420.31-0.14-0.040.21-0.090.060.47-0.13
0.870.280.260.60.850.230.730.19-0.04-0.480.760.470.420.680.720.890.680.720.30.10.70.370.670.660.3
0.650.970.350.970.080.940.880.180.79-0.970.59-0.080.42-0.040.440.560.720.790.960.180.920.980.930.710.96
0.55-0.10.140.130.77-0.130.23-0.01-0.40.030.170.650.68-0.040.40.630.280.28-0.08-0.020.23-0.040.140.38-0.06
0.770.260.050.580.690.280.730.390.05-0.530.660.190.720.440.40.780.730.770.330.440.680.390.650.70.2
0.990.430.130.720.850.440.80.36-0.02-0.630.730.610.890.560.630.780.880.880.480.150.830.540.750.910.4
0.910.580.230.810.610.60.850.30.21-0.790.820.420.680.720.280.730.880.970.630.280.880.680.820.940.56
0.940.660.230.870.570.660.90.320.32-0.850.820.310.720.790.280.770.880.970.70.280.930.750.890.950.63
0.580.990.140.93-0.040.990.80.340.81-0.940.4-0.140.30.96-0.080.330.480.630.70.10.851.00.870.680.95
0.180.070.180.220.130.050.41-0.010.08-0.210.3-0.040.10.18-0.020.440.150.280.280.10.220.130.320.20.04
0.880.830.30.980.450.810.970.290.52-0.930.760.210.70.920.230.680.830.880.930.850.220.890.980.880.81
0.640.990.180.960.030.980.850.330.79-0.960.47-0.090.370.98-0.040.390.540.680.751.00.130.890.910.720.95
0.820.850.290.980.350.820.990.30.61-0.950.750.060.670.930.140.650.750.820.890.870.320.980.910.80.82
0.950.630.060.810.610.660.820.450.19-0.790.660.470.660.710.380.70.910.940.950.680.20.880.720.80.57
0.50.970.430.9-0.080.930.750.020.85-0.880.44-0.130.30.96-0.060.20.40.560.630.950.040.810.950.820.57
Click cells to compare fundamentals

Blueprint Medicines Account Relationship Matchups

Blueprint Medicines fundamental ratios Accounts

202020212022202320242025 (projected)
Total Assets1.7B1.3B1.3B1.0B1.2B784.9M
Short Long Term Debt Total89.6M111.4M562.7M774.1M890.2M934.8M
Other Current Liab98.0M113.7M(295.5M)128.0M147.2M154.6M
Total Current Liabilities130.8M149.8M183.2M214.9M247.2M259.5M
Total Stockholder Equity1.5B970.7M514.7M130.6M150.2M142.7M
Other Liab47.7M35.8M28.4M437.0M502.5M527.6M
Property Plant And Equipment Net101.7M120.9M115.2M115.7M133.0M139.6M
Current Deferred Revenue12.6M36.6M448.6M812K933.8K887.1K
Net Debt(595.0M)(98.5M)122.7M702.8M808.3M848.7M
Retained Earnings(631.4M)(1.3B)(1.8B)(2.3B)(2.1B)(2.0B)
Accounts Payable4.4M8.3M2.7M4.7M5.4M3.9M
Cash684.6M209.9M119.7M71.3M82.0M77.9M
Non Current Assets Total790.6M698.2M303.3M240.9M277.0M236.9M
Non Currrent Assets Other11.1M19.8M26.8M40.9M47.0M49.4M
Other Assets569.3M19.8M26.8M1.01.151.09
Cash And Short Term Investments1.5B1.0B1.1B710.6M817.2M656.9M
Common Stock Total Equity49K58K59K60K69K41.4K
Common Stock Shares Outstanding56.2M58.5M59.6M60.6M69.6M43.6M
Liabilities And Stockholders Equity1.7B1.3B1.3B1.0B1.2B784.9M
Non Current Liabilities Total117.5M131.7M652.0M703.7M809.3M849.7M
Other Current Assets22.0M18.1M35.0M33.4M38.4M51.4M
Other Stockholder Equity2.1B2.3B2.4B2.5B2.8B3.0B
Total Liab248.3M281.5M835.2M918.6M1.1B1.1B
Property Plant And Equipment Gross101.7M146.3M146.5M154.1M177.3M186.1M
Total Current Assets927.8M554.0M1.0B808.4M929.7M548.0M
Accumulated Other Comprehensive Income(5.2M)(4.1M)(10.4M)(3.5M)(3.1M)(3.3M)
Short Term Debt15.9M16.2M27.4M81.4M93.6M98.3M
Common Stock58K59K60K61K70.2K43.7K
Property Plant Equipment38.4M34.1M30.7M33.3M38.3M22.7M
Net Tangible Assets464.4M1.5B1.2B514.7M591.9M613.2M
Net Receivables25.3M37.0M36.9M43.2M49.7M52.1M
Short Term Investments187.2M267.2M825.3M639.4M735.3M772.0M
Long Term Investments677.9M557.5M133.5M84.3M97.0M92.1M
Retained Earnings Total Equity(945.2M)(631.4M)(1.3B)(1.8B)(1.6B)(1.6B)
Capital Surpluse1.4B2.1B2.3B2.4B2.7B1.5B
Inventory8.6M21.8M29.7M21.2M24.4M25.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Blueprint Medicines Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Blueprint Medicines' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Blueprint Medicines Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Blueprint Medicines Corp Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.09)
Revenue Per Share
6.986
Quarterly Revenue Growth
1.266
Return On Assets
(0.15)
Return On Equity
(0.50)
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.